Arvinas Inc.

Nasdaq ARVN · New Haven, CT

Works in Dermatology · ENT · Genetic & rare · GI & liver · Hematology · Immunology · Infectious disease · Metabolic & endocrine · Neurology · Oncology · Renal & urogenital · Respiratory · Women's health

Arvinas Inc. is a clinical trial sponsor based in New Haven, CT, listed as Nasdaq ARVN. It has 3 active clinical trials with 904 planned participants, across 13 therapeutic areas. Since 2021 it has completed 2 trials and stopped 0 early.

Trial track record · since 2021

3Active trials904 planned participants
2Completed1 with results posted
0Stopped earlyterminated, withdrawn or suspended

Financials · Nasdaq ARVN

Cash and equivalents
R&D expense
Net income (loss)
Cash runway

Pipeline · 3 active trials

StageTrialStatus

Questions about Arvinas Inc

See the rest of this profile

A free account shows the trial list, the financials and the fundraising filings. Pro adds a watchlist: one email when FDA acts on a company you name.

Trial counts are as the sponsor reported them to ClinicalTrials.gov, for trials changed since 2021; latest update 2026-10-13.

Approve Suite is not affiliated with Arvinas Inc..

See something wrong on this page? Write to info@approvesuite.com and we will check it against the source. How corrections work.